Programmed death-ligand 1 (PD-L1) / programmed cell death protein 1 (PD1) targeting immunotherapy is a promising new treatment option in locally advanced (unresectable) or metastatic gastric adenocarcinoma (GC). This evidence concerns the gene PDCD1 and gastric cancer.